Unicycive Therapeutics: Two CRLs, One Fixable Problem
We bridge the gap between financial information and actionable insight by providing unrivaled coverage on all asset classes and access to best-in-class tools. FDA's second CRL was solely due to unresolved manufacturing issues; efficacy and safety remain unchallenged, with a facility inspection in India scheduled soon. OLC demonstrates >50% pill burden reduction and strong efficacy in hyperphosphatemia, positioning UNCY as best-in-class among phosphate binders.
- ▪We bridge the gap between financial information and actionable insight by providing unrivaled coverage on all asset classes and access to best-in-class tools.
- ▪FDA's second CRL was solely due to unresolved manufacturing issues; efficacy and safety remain unchallenged, with a facility inspection in India scheduled soon.
- ▪OLC demonstrates >50% pill burden reduction and strong efficacy in hyperphosphatemia, positioning UNCY as best-in-class among phosphate binders.
Seeking Alpha files mainly under finance. We currently carry 6,421 of its stories.
Opening excerpt (first ~120 words) tap to expand
{"@context":"https://schema.org","@type":"BreadcrumbList","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https://seekingalpha.com/"},{"@type":"ListItem","position":2,"name":"Healthcare ","item":"https://seekingalpha.com/stock-ideas/healthcare"}]}{"@context":"https://schema.org","@type":"NewsArticle","mainEntityOfPage":{"@type":"WebPage","@id":"https://seekingalpha.com/article/4925611-unicycive-therapeutics-two-crls-one-fixable-problem"},"author":{"@type":"Person","name":"Bhavneesh Sharma","url":"https://seekingalpha.com/author/bhavneesh-sharma"},"publisher":{"@context":"https://schema.org","@type":"Organization","address":{"@type":"PostalAddress","streetAddress":"244 5th Ave","addressLocality":"New…
Excerpt limited to ~120 words for fair-use compliance. The full article is at Seeking Alpha.
Discussion
0 commentsMore from Seeking Alpha
